Table 2.

Toxicities among the 14 patients who continued on study post-C1D17 Ki67 evaluation

	Grade
Toxicity	1	2		3	4	N (%)
Fatigue	10 (71.4%)	3 (21.4%)		0	0	13 (92.9%)
Hyperglycemia	10 (71.4%)	3 (21.4%)		0	0	13 (92.9%)
Maculopapular rash	4 (28.6%)	2 (14.3%)		4 (28.6%)	0	10 (71.4%)
Pruritus	3 (21.4%)	2 (14.3%)		2 (14.3%)	0	7 (50%)
Dry skin	5 (35.7%)	2 (14.3%)		0	0	7 (50%)
Nausea	4 (28.6%)	1 (7.1%)		0	0	5 (35.7%)
ALT increase	0	0		0	1 (7.1%)	1 (7.1%)
AST increase	0	0		0	1 (7.1%)	1 (7.1%)
Angioedema	0	1 (7.1%)		0	0	1 (7.1%)
Sinus bradycardia	0	1 (7.1%)		0	0	1 (7.1%)
Vaginal dryness	0	1 (7.1%)		0	0	1 (7.1%)